Primary Climate Goal
Astellas Pharma's target annual Scope 1 + 2 emissions for 2031 should be equal to 86 Kt = 30% * 123 Kt, according to the company's stated climate goal.
In order to achieve this goal, Astellas Pharma would need to reduce its emissions at least by -3.7 Kt per annum over the period from 2022 to 2031:
-3.7 Kt = ( 86 Kt - 123 Kt ) / (2031 - 2021)
This translates into a -3% reduction in 2022.
The projected range shown on the chart is based on the Exerica's algorithm which takes account of both the company's stated goal and its past performance.
Astellas Pharma aims to reduce Scope 1 + 2 by 30% by 2031 from a base year 2021
Science Based Targets initiative In October 2021 SBTi developed and launched world's first net zero standard, providing framework and tools for companies to set science-based net zero targets and limit global temperature rise above pre-industrial levels to 1.5 °C.
In October 2021 SBTi developed and launched world's first net zero standard, providing framework and tools for companies to set science-based net zero targets and limit global temperature rise above pre-industrial levels to 1.5 °C.
GHG emissions and Carbon intensity
Scope 1 + 2 GHG emissions (in tons of CO2e) divided by the company's Revenues (in USDm) for the same period
Astellas Pharma reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 March 2021 at 123 Kt (-44 /-26.2% y-o-y). Also positively, carbon intensity decreased to 14 t (-1.6 /-10.1% y-o-y).
Astellas Pharma's Scope 3 emissions plunged to 194 Kt (
The company is committed to reducing Scope 1 + 2 by 30% by 2031 from a base year 2021, which translates into the estimated reduction of -3.7 Kt per annum over the period of FY2022 - FY2031. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.
Astellas Pharma also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. Astellas Pharma Inc. commits to reduce absolute scope 1 and 2 GHG emissions 63% by FY2030 from a FY2015 base year. Astellas Pharma Inc.commits to reduce absolute scope 3 GHG missions 37.5% by FY2030 from a FY2015 base year.